Clinical trial · Observational
Synthetic Metabolic and Genetic Networks for Medical Diagnosics
Development of Synthetic Metabolic and Genetic Networks for the Detection of Urogenital Cancers
NCT04518072CI-TRIAL-00090847SynBioDiagterminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): delay in erolement, decision of the sponsor
Summary
Brief summary (as posted)
This is a category 3 human study, prospective, comparative, in parallel groups. A comparative qualitative and quantitative analysis of several markers in 250 samples is proposed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Prostate | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Biopsy prostatic group
- description
- positive biopsy (100) negative biopsy (100)
- interventionNames
- Other: Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)
- label
- Control group
- description
- No prostate cancer (50)
- interventionNames
- Other: Blood sample (1 EDTA tube, 1 SST tube, 1 Streck tube) and urine sample (100 ml)
Primary outcomes (1)
- measure
- Ability to detect and quantify biomarkers such as PSA in samples using biosensors platform
- timeFrame
- Up to 69 months
- description
- The positive signal is bases on a permeation in E. coli cell membrane and recombinase switches.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men aged over 18 * Informed, written consent of the patient for the biological collection * Subject affiliated to a French social security scheme or beneficiary of such a scheme Patients specific inclusion criteria : \- Admitted to care prostate disease or suspicion of prostate cancer and with a positive or negative PSA blood result Controls specific inclusion criteria : \- Man free from all prostate or bladder pathologies Exclusion Criteria: * Patient under legal protection * Persons deprived of their liberty, protected adults or vulnerable persons * Participants may withdraw their consent at any time and for any reason whatsoever without incurring any negative consequences without change in their usual care Controls specific non-inclusion criteria : * Patient with current prostatic or urinary infection * History of treatment for prostate cancer other than surveillance management
References
Publications (0)
Data not yet available
No reference posted for this study.